Form 8-K - Current report:
SEC Accession No. 0001140361-26-006981
Filing Date
2026-02-26
Accepted
2026-02-26 16:21:19
Documents
14
Period of Report
2026-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20066645_8k.htm   iXBRL 8-K 29427
2 EXHIBIT 99.1 ef20066645_ex99-1.htm EX-99.1 105935
6 image00001.jpg GRAPHIC 4415
  Complete submission text file 0001140361-26-006981.txt   279631

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rckt-20260226.xsd EX-101.SCH 3878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rckt-20260226_lab.xml EX-101.LAB 21967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rckt-20260226_pre.xml EX-101.PRE 16053
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20066645_8k_htm.xml XML 4057
Mailing Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118
Business Address 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118 646-440-9100
ROCKET PHARMACEUTICALS, INC. (Filer) CIK: 0001281895 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36829 | Film No.: 26688578
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)